Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Maze Therapeutics, Inc.MAZE · Entity 1775 | President, R&D & CMO | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Maze Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 16,141 · Balance 16,141 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Row 2 · 2026-10-01 · Sale · Disposed 16,141 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.47 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2032-10-26 | Direct | 144,521 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Disposed 16,141 · Balance 144,521 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3: The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.47 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 21:51 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 25,156 | $40.20 | $1,011,298.87 |
DisclosureSEC source: 0002050172-26-000006 · form4-01092026_090123.xml · nonDerivative · entry 2 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.55 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:51 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 25,156 | $10.42 | $262,125.52 |
DisclosureSEC source: 0002050172-26-000006 · form4-01092026_090123.xml · nonDerivative · entry 1 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:31 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 412 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050172-26-000003 · form4-01062026_090146.xml · derivative · entry 6 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,563 Underlying: Common Stock · 412 shares Expires 2032-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:31 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 412 | $40.00 | $16,480.00 |
DisclosureSEC source: 0002050172-26-000003 · form4-01062026_090146.xml · nonDerivative · entry 4 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:31 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 412 | $10.42 | $4,293.04 |
DisclosureSEC source: 0002050172-26-000003 · form4-01062026_090146.xml · nonDerivative · entry 3 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:31 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,432 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050172-26-000003 · form4-01062026_090146.xml · derivative · entry 5 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,975 Underlying: Common Stock · 4,432 shares Expires 2032-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:31 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 4,432 | $40.43 | $179,187.53 |
DisclosureSEC source: 0002050172-26-000003 · form4-01062026_090146.xml · nonDerivative · entry 2 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.965 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:31 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 4,432 | $10.42 | $46,181.44 |
DisclosureSEC source: 0002050172-26-000003 · form4-01062026_090146.xml · nonDerivative · entry 1 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:22 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050172-25-000007 · form4-12312025_091232.xml · derivative · entry 4 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 342,407 Underlying: Common Stock · 45,000 shares Expires 2032-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:22 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 17,200 | $40.93 | $703,930.64 |
DisclosureSEC source: 0002050172-25-000007 · form4-12312025_091232.xml · nonDerivative · entry 3 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.73 to $41.51 per share, inclusive. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:22 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 27,800 | $40.34 | $1,121,424.20 |
DisclosureSEC source: 0002050172-25-000007 · form4-12312025_091232.xml · nonDerivative · entry 2 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,200 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.71 to $40.705 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:22 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 45,000 | $10.42 | $468,900.00 |
DisclosureSEC source: 0002050172-25-000007 · form4-12312025_091232.xml · nonDerivative · entry 1 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002050172-25-000004 · form4-09242025_080911.xml · derivative · entry 1 Bernstein Harold · CIK 0002050172 · President, R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.